AFP and hepatocellular carcinoma: One reason could be the relatively low sensitivity of AFP in detecting HCC patients at the early stages of the disease (BCLC stage 0, A, and B is 18%, 64%, and 18% of the enrolled patients, respectively), in addition to the FL size (<3 cm in 40.7% of the patients) and number (single FL in 64% of the HCC patients).